Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MSLE
STRONG SELLREMOVESatellos Bioscience Inc. · Healthcare · Canada · $119M · Avg Vol: $217K/d
A micro-cap biotech company with high binary trial risk, lacking the validated manufacturing platform or cash flows of a high-quality CDMO.
COMPANY DESCRIPTION
Satellos Bioscience Inc. is a biotechnology company developing small molecule therapeutics to address Duchenne Muscular Dystrophy and other muscle degenerative diseases. The company's competitive advantage is its proprietary 'Regenomics' platform, which aims to modulate muscle stem cell function to promote regeneration. Satellos is an early-stage clinical company focused on pioneering novel approaches to muscle repair and regeneration.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — |
| EPS | — | -0.47 | -0.73 | -2.16 | -1.70 | — |
| Shares | — | 20.8M | 20.8M | 13.8M | 15.5M | -25.8% |
| Debt | — | 2.1M | 2.7M | 3.6M | 4.1M | 25.3% |
| Equity | — | 2.5M | 30.8M | 47.2M | 27.8M | 123.7% |
| Op CF | — | -4.3M | -8.7M | -18.3M | -23.6M | — |
| Inv CF | — | -2,210 | -13.2M | 4.7M | -9.4M | — |
| Fin CF | — | 2.0M | 38.0M | 37.6M | 2.2M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MSLE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MSLE | Satellos Bioscience Inc.(you) | $119M | 10 | STRONG SELL |
| ENGN | enGene Therapeutics Inc. | $114M | 8 | STRONG SELL |
| PMN | ProMIS Neurosciences, Inc. | $97M | 15 | STRONG SELL |
| OBI.L | Ondine Biomedical Inc. | $101M | 20 | SELL |
| MIST | Milestone Pharmaceuticals Inc. | $161M | 1 | STRONG SELL |
| HELP | Cybin D/B/A Helus Pharma | $245M | 6 | STRONG SELL |
| EDSA | Edesa Biotech, Inc. | $61M | 17 | STRONG SELL |
| NGEN | NervGen Pharma Corp. | $244M | 1 | STRONG SELL |
| QNTM.CN | Quantum BioPharma Ltd. | $45M | 2 | STRONG SELL |
| MDNA.TO | Medicenna Therapeutics Corp. | $27M | 1 | STRONG SELL |
Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%